Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC

• Status: Recruiting
• Trial end date: 2025-02-04
• Target enrollment: 0
• Participant gender: All

Summary

To Study Perioperative PD-1 Inhibitor and Cesium-131 Interstitial Brachytherapy in patients with locally recurrent HNSCC eligible for salvage surgery.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Cincinnati
• Collaborator: IsoRay Medical, Inc.
• Treatments: Pembrolizumab

Criteria

Inclusion Criteria:

• locally recurrent HNSCC and be eligible for salvage surgery

• If patient received radiation therapy in the past, they should have recovered from the acute toxicity to- tumor needs to be deemed resectable

Exclusion Criteria:

• Exposed carotid artery preoperatively requiring sacrifice or bypass intra-operatively

• Patients with active pharyngo-cutaneous

• Patients with more than one site of distant metastatic disease

• Prior immune-based anticancer therapy within last six months